SUZHOU, CHINA

With the Second-Generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the “Retrievable Era” using TAVR products

The TaurusElite® Transcatheter Aortic Valve Replacement System (hereinafter referred to as “TaurusElite®“) developed by Peijia Medical (9996.HK) is approved for marketing by the National Medical Products Administration (NMPA) in June 2021 (Reg. No. GXZZ 20213130464). This approval will accelerate the transition of China TAVR practice into retrievable era. TaurusElite® is the second-generation TAVR system developed by Peijia…

thaipr.net

28 มิ.ย. 64

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

– Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy – Sugemalimab is also the world’s first anti-PD-1/PD-L1 monoclonal antibody covering both locally advanced/unresectable (stage III) and metastatic (stage…

thaipr.net

28 พ.ค. 64

GCLSI Successfully Raises CNY2.5 billion ($US386 million) through Private Placement Share Offering

GCL System Integration Technology Co. Ltd (“GCLSI” or “the Company”) (Shenzhen:002506), a leading photovoltaics (PV) company in China, announced on January 21 that it successfully raised 2.5 billion yuan ($US386 million) through a private placement offering, which will accelerate the implementation of the Company’s “dual-core business(photovoltaic and semiconductor)” strategy. In a report on non-public…

thaipr.net

27 ม.ค. 64
1 2 3 4 5

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.